- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02822053
Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms
July 1, 2016 updated by: First Affiliated Hospital of Zhejiang University
The purpose of this study is to evaluate the safety and efficacy of ultrasonography (US) -guided laser ablation liver, kidney, pancreas, lung and retroperitoneal tumors, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients.
Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guo Tian, Master
- Phone Number: +86 13600529967
- Email: 871035504@qq.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital of Zhejiang University
-
Contact:
- Guo Tian, Master
- Phone Number: +86 13600529967
- Email: 871035504@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter),
- Patients with Child-Pugh A/B,
- Patients with PLT ≥ 50*10E9/L and PT ≤ 20s.
Exclusion Criteria:
- Patients with blood coagulation dysfunction, ChildPugh ≥3, severe cardiopulmonary disease, intolerant anesthesia and upper gastrointestinal bleeding in shock.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: US-guided laser ablation for refractory neoplasms
The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s.
Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
100 patients of refractory neoplasms with image-guided laser ablation-related effectivity as assessed by MRI
Time Frame: up to 24 months
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Influence of ablative margin on local tumor progression and survival in patients with HCC </=4 cm after laser ablation. Acta Radiol. 2012 May 1;53(4):394-400. doi: 10.1258/ar.2012.110471. Epub 2012 Mar 5.
- Wu X, Zhou P, Ma S, Tian S, Deng J, Zhao Y. [Ultrasound-guided laser thermal ablation for treatment of small liver cancer at high-risk sites]. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Jan;36(1):120-5. Chinese.
- Di Costanzo GG, D'Adamo G, Tortora R, Zanfardino F, Mattera S, Francica G, Pacella CM. A novel needle guide system to perform percutaneous laser ablation of liver tumors using the multifiber technique. Acta Radiol. 2013 Oct;54(8):876-81. doi: 10.1177/0284185113489825. Epub 2013 May 23.
- Zou X, Liu Q, Zhou X, He G, Yu M, Han Z, Meng X, Su H. Ultrasound-guided percutaneous laser and ethanol ablation of rabbit VX2 liver tumors. Acta Radiol. 2013 Mar 1;54(2):181-7. doi: 10.1258/ar.2012.110723.
- Clements LW, Collins JA, Weis JA, Simpson AL, Adams LB, Jarnagin WR, Miga MI. Evaluation of model-based deformation correction in image-guided liver surgery via tracked intraoperative ultrasound. J Med Imaging (Bellingham). 2016 Jan;3(1):015003. doi: 10.1117/1.JMI.3.1.015003. Epub 2016 Mar 23.
- Jiang T, Deng Z, Tian G, Chen F, Bao H, Li J, Wang W. Percutaneous laser ablation: a new contribution to unresectable high-risk metastatic retroperitoneal lesions? Oncotarget. 2017 Jan 10;8(2):2413-2422. doi: 10.18632/oncotarget.13897.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
June 1, 2018
Study Registration Dates
First Submitted
June 20, 2016
First Submitted That Met QC Criteria
July 1, 2016
First Posted (Estimate)
July 4, 2016
Study Record Updates
Last Update Posted (Estimate)
July 4, 2016
Last Update Submitted That Met QC Criteria
July 1, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LA-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Neoplasms
-
First Affiliated Hospital of Zhejiang UniversityUnknownRefractory NeoplasmsChina
-
First Affiliated Hospital of Zhejiang UniversityUnknownRefractory NeoplasmsChina
-
SCRI Development Innovations, LLCBayerCompletedRefractory MalignancyUnited States
-
University of Southern CaliforniaTerminated
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI); Novartis PharmaceuticalsCompleted
-
The First Affiliated Hospital of Xiamen UniversityRecruitingRefractory Solid TumorChina
-
The First Affiliated Hospital of Xiamen UniversityRecruitingRefractory Solid TumorChina
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Dr. Tapas K. Das GuptaCompletedRefractory Solid TumorsUnited States
-
M.D. Anderson Cancer CenterRecruitingRefractory Solid TumorsUnited States
Clinical Trials on US-guided laser ablation for refractory neoplasms
-
First Affiliated Hospital of Zhejiang UniversityUnknownRefractory NeoplasmsChina
-
Xijing HospitalUnknownHypertrophic Obstructive CardiomyopathyChina
-
Urological Research Network, LLCRecruitingCancer of the Prostate | Neoplasms ProstateUnited States
-
Mayo ClinicWithdrawn
-
Henry Ford Health SystemMedtronicRecruitingLaser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine MetastasesNeoplasm Metastasis | Spinal Cord Diseases | Spinal Cord Compression | Spine Metastases | Spinal Cord TumorUnited States
-
Radboud University Medical CenterZiekenhuisgroep Twente; Canisius-Wilhelmina HospitalCompletedMRI | Prostate Cancer | Focal Laser AblationNetherlands
-
Seoul National University HospitalPhilips HealthcareCompletedHepatocellular Carcinoma
-
Profound Medical Inc.CompletedProstate CancerUnited States, Canada, Germany
-
MedtronicNeuroCompleted
-
Adagio MedicalRecruitingAtrial FibrillationUnited Kingdom, Netherlands, Czechia, Canada, Belgium, Ireland